Urolithin A regulates gut: liver axis to ameliorate alcohol-associated liver disease
Our findings suggest that the simultaneous targeting of gut barrier dysfunction, inflammation, and hepatic steatosis by treatment with UroA may offer new possibilities for combating ALD. Moreover, our results suggest that UroA-mediated protective activities against EtOH-induced gut barrier dysfunction and inflammation in ALD are dependent on intestinal epithelial cell-AHR.
Authors
- Raj Singh (ORCID: https://orcid.org/0000-0002-6331-9196)
- Sweta Ghosh (ORCID: https://orcid.org/0000-0003-0613-8687)
- Venkatakrishna R. Jala (ORCID: https://orcid.org/0000-0002-4206-7305)
- Vatsalya Vatsalya (ORCID: https://orcid.org/0000-0001-6764-6891)
- Praveen Kumar Vemula (ORCID: https://orcid.org/0000-0003-0279-4230)
- Zachary Matthew Vanwinkle
- Craig James McClain
- Bodduluri Haribabu
Institutions
- National Institutes of Health (US)
- University of Louisville (US)
- Institute for Stem Cell Biology and Regenerative Medicine (IN)
- Louisville VA Medical Center (US)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-01-19
- DOI
- https://doi.org/10.3389/fphar.2025.1706111
- Primary Topic
- Pomegranate: compositions and health benefits
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Institute on Alcohol Abuse and Alcoholism
- National Cancer Institute
- National Institute of General Medical Sciences
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute of Environmental Health Sciences